Novel treatment of allergic fungal sinusitis using omalizumab

A case report of recalcitrant allergic fungal sinusitis (AFS) refractory to systemic corticosteroids and multiple functional endoscopic sinus surgeries (FESSs) treated with anti-IgE antibody omalizumab is reported. AFS is often classified with chronic rhinosinusitis (CRS). Although similar symptoms...

Descripción completa

Detalles Bibliográficos
Autores principales: Evans, Martin Oman, Coop, Christopher Albert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: OceanSide Publications, Inc. 2014
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4275465/
https://www.ncbi.nlm.nih.gov/pubmed/25565055
http://dx.doi.org/10.2500/ar.2014.5.0098
_version_ 1782350128160440320
author Evans, Martin Oman
Coop, Christopher Albert
author_facet Evans, Martin Oman
Coop, Christopher Albert
author_sort Evans, Martin Oman
collection PubMed
description A case report of recalcitrant allergic fungal sinusitis (AFS) refractory to systemic corticosteroids and multiple functional endoscopic sinus surgeries (FESSs) treated with anti-IgE antibody omalizumab is reported. AFS is often classified with chronic rhinosinusitis (CRS). Although similar symptoms are among the two diseases, AFS has a unique pathophysiology. Patients with AFS demonstrate type 1 hypersensitivity to fungal allergens, increased total serum IgE, increased CD8(+) T-cell prevalence, and IL-4 and IL-5 response. Omalizumab should be considered in the treatment of AFS.
format Online
Article
Text
id pubmed-4275465
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher OceanSide Publications, Inc.
record_format MEDLINE/PubMed
spelling pubmed-42754652015-01-02 Novel treatment of allergic fungal sinusitis using omalizumab Evans, Martin Oman Coop, Christopher Albert Allergy Rhinol (Providence) Articles A case report of recalcitrant allergic fungal sinusitis (AFS) refractory to systemic corticosteroids and multiple functional endoscopic sinus surgeries (FESSs) treated with anti-IgE antibody omalizumab is reported. AFS is often classified with chronic rhinosinusitis (CRS). Although similar symptoms are among the two diseases, AFS has a unique pathophysiology. Patients with AFS demonstrate type 1 hypersensitivity to fungal allergens, increased total serum IgE, increased CD8(+) T-cell prevalence, and IL-4 and IL-5 response. Omalizumab should be considered in the treatment of AFS. OceanSide Publications, Inc. 2014 /pmc/articles/PMC4275465/ /pubmed/25565055 http://dx.doi.org/10.2500/ar.2014.5.0098 Text en Copyright © 2014, OceanSide Publications, Inc., U.S.A. This publication is provided under the terms of the Creative Commons Public License ("CCPL" or "License"), in attribution 3.0 unported (Attribution Non-Commercial No Derivatives (CC BY-NC-ND)), further described at: http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode. The work is protected by copyright and/or other applicable law. Any use of the work other then as authorized under this license or copyright law is prohibited.
spellingShingle Articles
Evans, Martin Oman
Coop, Christopher Albert
Novel treatment of allergic fungal sinusitis using omalizumab
title Novel treatment of allergic fungal sinusitis using omalizumab
title_full Novel treatment of allergic fungal sinusitis using omalizumab
title_fullStr Novel treatment of allergic fungal sinusitis using omalizumab
title_full_unstemmed Novel treatment of allergic fungal sinusitis using omalizumab
title_short Novel treatment of allergic fungal sinusitis using omalizumab
title_sort novel treatment of allergic fungal sinusitis using omalizumab
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4275465/
https://www.ncbi.nlm.nih.gov/pubmed/25565055
http://dx.doi.org/10.2500/ar.2014.5.0098
work_keys_str_mv AT evansmartinoman noveltreatmentofallergicfungalsinusitisusingomalizumab
AT coopchristopheralbert noveltreatmentofallergicfungalsinusitisusingomalizumab

Ejemplares similares